Patient assessment of an electronic device for subcutaneous self-injection of interferon ß-1a for multiple sclerosis: an observational study in the UK and Ireland
Authors:
Open Access
- 1 January 2012
- journal article
- research article
- Published by Taylor & Francis in Patient Preference and Adherence
- Vol. 6, 55-61
Abstract
Peer reviewed article authored by (D'Arcy C, Thomas D, Stoneman D, Parkes L). Read article or submit your manuscript for publishing.Keywords
This publication has 22 references indexed in Scilit:
- Patient-rated suitability of a novel electronic device for self-injection of subcutaneous interferon beta-1a in relapsing multiple sclerosis: an international, single-arm, multicentre, Phase IIIb studyBMC Neurology, 2010
- Addressing the need for increased adherence to multiple sclerosis therapy: can delivery technology enhance patient motivation?Expert Opinion on Drug Delivery, 2009
- Update on Inflammation, Neurodegeneration, and Immunoregulation in Multiple SclerosisClinical Neuropharmacology, 2009
- Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MSNeurology, 2006
- Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”Annals of Neurology, 2005
- PRISMS-4: Long-term efficacy of interferon-β-1a in relapsing MSNeurology, 2001
- Defining the clinical course of multiple sclerosisNeurology, 1996
- Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosisAnnals of Neurology, 1996
- Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosisNeurology, 1995
- Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosisNeurology, 1993